Although the clinical usefulness of elevated CEA and CA15-3 levels for predicting patient prognosis in early breast cancers has been established, these patients usually accounted for a small proportion of the population, thus emphasizing the need for more sensitive markers [14]. The gene discussed is CEACAM5; the disease is breast carcinoma.